December 22, 2021
Kissei Pharmaceutical said on December 21 that its tyrosine kinase inhibitor fostamatinib (R788) achieved the primary endpoint in the first period of a Japan PIII study for the treatment of chronic immune thrombocytopenic purpura (ITP). The company aims to file...read more